Platelet activation and lipid peroxidation in patients with acute ischemic stroke
August 1997
Article
| Related Files |
|---|
|
(9259748.pdf, 0.5MB) |
|
Redirect to Publisher's version
(Publisher's version.url.txt, 56 bytes) |
BACKGROUND AND PURPOSE: Both platelet activation and lipid peroxidation are potential sources of vasoactive eicosanoids that can be produced via the cyclooxygenase pathway, ie, thromboxane (TX) A2, or by free radical-catalyzed peroxidation of arachidonic acid, ie, isoprostanes. We investigated the biosynthesis of TXA2 and F2-isoprostanes, as reflected by the urinary excretion of 11-dehydro-TXB2 and 8-epi-prostaglandin (PG) F2 alpha respectively, in 62 consecutive patients (30 men, 32 women; mean age, 67 +/- 14 years) with acute ischemic stroke. METHODS: At least two consecutive 6-hour urine samples were obtained during the first 72 hours after onset of symptoms. Urinary eicosanoids were measured by previously described radioimmunoassays. RESULTS: Repeated periods of enhanced thromboxane biosynthesis were found in 52% of patients. Urinary 11-dehydro-TXB2 averaged 221 +/- 207 (mean +/- SD; n = 197; range, 13 to 967) pmol/mmol creatinine in 30 patients treated with cyclooxygenase inhibitors (mostly aspirin) at the time of study versus 392 +/- 392 (n = 186; range, 26 to 2533) in 32 untreated patients (P < .001). The corresponding values for 8-epi-PGF2 alpha excretion were 74 +/- 42 (range, 14 to 206) and 83 +/- 65 (range, 24 to 570) pmol/mmol creatinine (P > .05). The correlation between the two metabolites was moderate in both untreated patients (r = .41, P < .001) and patients with cyclooxygenase inhibitors (r = .31, P < .001). In a multiple regression analysis, increased thromboxane production was independently associated with severity of stroke on admission, atrial fibrillation, and treatment with cyclooxygenase-inhibiting drugs. CONCLUSIONS: We conclude that during the first few days after an acute ischemic stroke (1) platelet activation occurs repeatedly in a cyclooxygenase-dependent fashion; (2) platelet activation is not associated with concurrent changes in isoprostane biosynthesis; (3) platelet activation is independently associated with stroke severity and atrial fibrillation; and (4) isoprostane biosynthesis is largely independent of platelet cyclooxygenase activity.
- Male
- Aged
- Female
- Humans
- Acute Disease
- Middle Aged
- Reference Values
- Thromboxane B2/analogs & derivatives/urine
- cerebral ischemia
- Atrial Fibrillation/blood/metabolism/urine
- Brain Ischemia/*blood/*metabolism/urine
- Cerebrovascular Disorders/*blood/*metabolism/urine
- Cyclooxygenase Inhibitors/therapeutic use
- Dinoprost/urine
- Lipid Peroxides/*metabolism
- Platelet Activation
- lipid peroxidation
- platelet activation
- thromboxanes
- patient
- 8- epi-pgf 2
- stroke
- 11- dehydro-txb 2
- epi-pgf
- dehydro-txb
- 11-
- article
- excretion
- study
- cyclooxygenase inhibitors
- level
- platelet
- atrial fibrillation
- cyclooxygenase
- roberts lj ii
- thromboxane
- value
- stroke severity
- platelet activation